The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to ...

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 ...

Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. | Despite making up a sizable ...

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...

With the full-scale launch of its latest surgical robot set for the middle of this year, Intuitive Surgical said that, to ...